In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses
- 22 December 2005
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 59 (1) , 13-20
Abstract
Objective: We tested the premise that cholinesterase inhibitor therapy should target butyrylcholinesterase (BuChE) in Alzheimer's disease (AD), not acetylcholinesterase (AChE) alone, because both enzymes hydrolyze acetylcholine, and BuChE is increased in AD cerebral cortex.Methods: To examine this issue in vivo, we quantified human cerebral cortical BuChE activity using tracer kinetic estimates (k3) of 1‐[11C]methyl‐4‐piperidinyl n‐butyrate ([11C]BMP) hydrolysis determined by positron emission tomography. Validation of the putative positron emission tomography method included regional distribution, positive correlation with age, and attenuation by the nonselective cholinesterase inhibitor physostigmine, but no attenuation by the AChE‐selective inhibitor donepezil. Positron emission tomography scans in AD patients (n = 15) and control subjects (n = 12) measured both BuChE (using [11C]BMP) and AChE activity (using N‐[11C] methylpiperidin‐4‐yl propionate, an established method).Results: As expected, AChE activity in AD cerebral cortex was decreased to 75 ± 13% of normal (p = 0.00001). Contrary to prediction, accompanying BuChE activity also was decreased to 82 ± 14% of normal (p = 0.001).Interpretation: Failure to observe increased [11C]BMP hydrolysis in vivo makes it less likely that incremental BuChE contributes importantly to acetylcholine hydrolysis in AD. The findings do not support the premise that inhibitor therapy should target BuChE so as to prevent increased levels of BuChE from hydrolyzing acetylcholine in AD cerebral cortex. Ann Neurol 2006Keywords
This publication has 45 references indexed in Scilit:
- Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2005
- Cholinesterase Inhibitors Used in the Treatment of Alzheimer???s DiseaseDrugs & Aging, 2004
- Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefitJournal of Neural Transmission, 2002
- Selective Inhibitors of ButyrylcholinesteraseDrugs & Aging, 2001
- Selectivity of Cholinesterase InhibitionCNS Drugs, 1999
- N-[11C]methylpiperidine esters as acetylcholinesterase substrates: an in vivo structure–reactivity studyNuclear Medicine and Biology, 1998
- Design and evaluation of radioactive acetylcholine analogs for mapping brain acetylcholinesterase (AchE) in vivoNuclear Medicine and Biology, 1994
- Molecular Forms of Acetylcholinesterase and Butyrylcholinesterase in the Aged Human Central Nervous SystemJournal of Neurochemistry, 1986
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984
- A New Clinical Scale for the Staging of DementiaThe British Journal of Psychiatry, 1982